The GLP-1 Research Landscape, Q2 2026
The incretin-axis research peptide category has expanded rapidly over the last five years. What was once a small set of GLP-1 receptor agonist research probes has grown into a multi-mechanism toolkit spanning single-receptor, dual-receptor, triple-receptor, and amylin-receptor compounds. For researchers entering the field — or for those revisiting it after a few years away — this is a snapshot of the current research peptide landscape as of mid-2026, with a focus on what each tool is mechanistically useful for.
All compounds discussed are research peptides supplied for in vitro and animal-study use only. Nothing here constitutes a clinical recommendation or human-use claim.
The receptor map
The incretin axis comprises three principal G-protein-coupled receptors that the current research peptide landscape engages:
- GLP-1R — glucagon-like peptide-1 receptor; pancreatic β-cells, hypothalamic neurons, gastric smooth muscle
- GIPR — glucose-dependent insulinotropic polypeptide receptor; β-cells, adipocytes, CNS
- GCGR — glucagon receptor; hepatocytes, adipose tissue, CNS
Plus the amylin/calcitonin receptor system (AMY1, AMY2, AMY3, CTR) — pancreatic islet, hypothalamus, area postrema — which is mechanistically distinct from the incretin receptors but functionally synergistic in metabolic models.
The current research peptide catalog provides compounds engaging different subsets of these receptors.
Single-receptor compounds
Semaglutide — the reference long-acting GLP-1 receptor monoagonist. A modified GLP-1(7-37) backbone with Aib² substitution and C18 fatty diacid albumin-binding modification. Most-cited comparator compound in the research literature for GLP-1R selectivity and downstream signaling studies. CAS 910463-68-2.
Liraglutide — the shorter-acting GLP-1 receptor monoagonist. C16 fatty acid at Lys26, plasma half-life of about 13 hours in animal models. Useful for research designs requiring shorter exposure windows than semaglutide can provide. CAS 204656-20-2.
These are research tools for GLP-1R-specific biology — for studies that need to isolate GLP-1R signaling without confounding from GIP or glucagon receptor activity.
Dual-receptor compounds
Tirzepatide — GLP-1R + GIPR dual agonist. 39 amino acids, GIP-derived backbone with C20 fatty diacid modification. The reference compound for dual incretin biology and biased GIPR signaling research. CAS 2023788-19-2. See tirzepatide mechanism deep-dive.
Survodutide — GLP-1R + GCGR dual agonist. 29 amino acids. Designed for combined GLP-1 + glucagon receptor pharmacology, with reported energy-expenditure and hepatic-lipid effects in preclinical models. CAS 2384032-94-2.
Mazdutide — GLP-1R + GCGR dual agonist (alternative chemistry). Engineered from the oxyntomodulin backbone, the natural dual-receptor parent peptide. Useful as a parallel research probe to survodutide for disentangling chemistry-specific from receptor-specific effects.
The two GLP-1/GCGR dual agonists (survodutide and mazdutide) and the GLP-1/GIPR dual agonist (tirzepatide) together allow disentangling the GIP vs. glucagon receptor contributions in metabolic-model research.
Triple-receptor compounds
Retatrutide — GLP-1R + GIPR + GCGR triple agonist. 39 amino acids. The most complex incretin pharmacology in current research distribution; engages all three target receptors at nanomolar affinity. Cryo-EM structural characterization of the bound state at each receptor was published in 2024. CAS 2381089-83-2. See retatrutide vs. semaglutide.
Amylin-pathway compounds
Cagrilintide — long-acting amylin analog. 37 amino acids with disulfide bond, C20 fatty diacid albumin-binding modification. Activates AMY receptors and CTR. Engages a parallel pathway to the incretin compounds, with reported additive effects when paired with GLP-1 agonists in preclinical models. CAS 1415456-99-3.
The amylin axis is mechanistically distinct from the incretin axis but converges on overlapping satiety circuits. For research designs probing combined amylin + incretin pharmacology, cagrilintide is the long-acting amylin tool.
What’s driving the field in 2026
A few mechanistic threads characterize the current research focus:
Biased agonism
The recognition that not all receptor-binding events produce equivalent downstream signaling has expanded into the incretin field. Tirzepatide’s biased GIPR signaling — with reduced β-arrestin recruitment relative to native GIP — is the prototype example. Research interest in characterizing biased agonism at GLP-1R, GIPR, and GCGR independently is increasing.
Receptor co-expression and tissue-specific effects
Different tissues co-express different subsets of the incretin receptors. The integrated metabolic effect of a multi-receptor agonist depends on which receptors are engaged in which tissue. Research designs disentangling tissue-specific contributions are an active area.
Hepatic-lipid biology
The glucagon receptor’s role in hepatic lipid metabolism has elevated GLP-1/GCGR dual agonists and the triple-receptor class as research tools for MASLD/MASH preclinical models. The 2024 Phase 2 MASH data for retatrutide and the 2024 survodutide Phase 2 data have positioned hepatic lipid biology as a major research focus.
Long-acting amylin combinations
The emerging research interest in combining GLP-1 agonists with cagrilintide-class amylin analogs is producing preclinical data on combined pathway engagement.
Practical considerations for research procurement
For researchers selecting compounds from this catalog:
- Compound selection follows from the research question. The choice between, say, semaglutide and tirzepatide is not about potency or duration — it’s about which receptor pharmacology the experimental design needs.
- CoA verification is non-negotiable. All of these compounds are large modified peptides with non-trivial synthesis. HPLC ≥99.0% purity, mass spec confirmation within ±0.5 Da, and net peptide content are the minimum verification points.
- Storage protocols are largely shared. Lyophilized at 2–8°C dry; reconstituted at 2–8°C in multi-dose diluent, use within 28 days. The DAC-modified compounds (in the GHRH-analog class) have somewhat distinct stability behavior.
- Renamed product catalogs. Many research-peptide vendors have moved to using scientific compound names rather than the marketed pharmaceutical brand names. This is a deliberate naming-convention shift that reflects the distinct nature of research-grade material vs. marketed pharmaceutical product.
Where the field is heading
Looking ahead through the rest of 2026 and into 2027, the research peptide catalog is likely to continue expanding along several axes:
- Engineered tissue-targeting — compounds that engage incretin receptors with tissue-specific delivery features
- Combined amylin + incretin engineered single-molecule compounds — peptides designed to engage both axes from a single backbone
- Refined biased-agonism profiles — compounds optimized for specific downstream pathway selectivity
- Compound-specific MASH/MASLD research tools — tailored for hepatic lipid biology investigation
Research Use Only. Not for use in or on humans or animals. Not a food, drug, cosmetic, or supplement.